Related Experiment Video

Updated: Jul 2, 2026

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant
08:52

Generation of Multivirus-specific T Cells to Prevent/treat Viral Infections after Allogeneic Hematopoietic Stem Cell Transplant

Published on: May 27, 2011

Combination of CsA, MTX and low-dose, short-course mycophenolate mofetil for GVHD prophylaxis

Y Lai1, J Ma, P Schwarzenberger

  • 1Department of Hematology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China. laiyongrong@hotmail.com

Bone Marrow Transplantation
|August 30, 2008
PubMed

Insights

A new prophylaxis regimen combining cyclosporine, MTX, and mycophenolate mofetil significantly reduced acute graft-versus-host disease (aGVHD) incidence in stem cell transplant patients. This approach improved survival outcomes without increasing relapse rates.

Area of Science:

  • Hematology
  • Immunology
  • Oncology

Background:

  • Acute graft-versus-host disease (aGVHD) is a major complication after allogeneic stem cell transplantation.
  • Current prophylaxis regimens have limitations in fully preventing or mitigating aGVHD.

Purpose of the Study:

  • To evaluate a novel prophylaxis regimen for reducing aGVHD incidence and severity.
  • To assess the impact of this regimen on chronic GVHD (cGVHD), transplant-related mortality, and survival outcomes.

Main Methods:

  • Prospective study of 100 patients undergoing HLA-matched or 1-antigen-mismatched allogeneic peripheral blood stem cell transplantation (SCT).
  • Regimen included cyclosporine, methotrexate (MTX), and a 30-day course of low-dose mycophenolate mofetil (500 mg/day).

Main Results:

  • The cumulative incidence of aGVHD (grades II-IV) was 16% (grades III-IV: 1%).
  • Cumulative incidence of cGVHD was 53% (extensive cGVHD: 28%).
  • Three-year disease-free survival was 77% in standard-risk and 30% in high-risk patients; overall survival was 77% and 37%, respectively.

Conclusions:

  • The novel regimen substantially decreased aGVHD risk without increasing relapse rates.
  • This prophylaxis strategy demonstrated a favorable impact on survival, particularly in standard-risk patients.
  • The combination therapy offers a promising approach for improving outcomes in allogeneic SCT.

More Related Videos

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System10:24

Automated Cell Enrichment of Cytomegalovirus-specific T cells for Clinical Applications using the Cytokine-capture System

Published on: October 5, 2015

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...